Analysts think CATX stock price could increase by 303%
Sep 05, 2025, 11:26 AM
-10.03%
What does CATX do
Perspective Therapeutics, based in Seattle, is a biotechnology company focused on developing radiopharmaceuticals for cancer treatment using the alpha-emitting isotope 212Pb. Their programs for melanoma and neuroendocrine tumors are in Phase I/IIa trials.
15 analysts think CATX stock price will increase by 303.39%. The current median analyst target is $14.28 compared to a current stock price of $3.54. The lowest analysts target is $5.05 and the highest analyst target is $21.00.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
